Pan-cancer analysis reveals CCL5/CSF2 as potential predictive biomarkers for immune checkpoint inhibitors
We demonstrated CCL5 and CSF2 as potential novel biomarkers for predicting the response to ICIs in patients with UC and ESCC. The predictive value of these biomarkers in other cancer types warrants further evaluation in future studies.
Authors
- Ze-Sen Du
- Wenqi Shi (ORCID: https://orcid.org/0000-0001-8972-7342)
- Yongqiang Zhao (ORCID: https://orcid.org/0000-0001-8729-9583)
- Weizhong Zheng (ORCID: https://orcid.org/0000-0002-3866-4932)
- Junwei Li (ORCID: https://orcid.org/0009-0000-0919-2289)
- Feng Pan (ORCID: https://orcid.org/0000-0003-2950-8222)
- Tian‐Tian Zhai
- Yichao Chen (ORCID: https://orcid.org/0000-0001-5725-1351)
- Haoyu Lin (ORCID: https://orcid.org/0000-0002-7365-1803)
- Si-Qi Qiu (ORCID: https://orcid.org/0000-0002-8870-0639)
- Chun‐Peng Liu
- Shan-Qing Cai
Institutions
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
- First Affiliated Hospital of Shantou University Medical College (CN)
- Shantou Central Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1186/s12935-024-03496-x
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Shantou University
- Natural Science Foundation of Guangdong Province
- Department of Education of Guangdong Province
- Shantou University Medical College